Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

AI Briefing

• – Arvinas and Pfizer to receive $85 million in upfront and transition payments for exclusive global rights of VEPPANU, with potential for additional $320 million in development, regulatory, and commercial milestones and tiered royalties on net sales.